中等结核负担地区类风湿关节炎患者生物制剂治疗中筛查指导预防策略下的结核风险
倾向评分加权后,预防组结核风险显著低于非预防组(HR 0.52,95%CI 0.32-0.86),提示在中等结核负担背景下现行筛查预防策略下筛查阴性患者结核风险仍较高。
要点
- 预防组结核发生率0.33/100人年,非预防组0.63/100人年
- 倾向评分加权后预防组结核风险显著降低(HR 0.52,95%CI 0.32-0.86)
- 非预防组结核风险在治疗第一年最高,随后逐年下降
核心结论
- 在中等结核负担地区,生物制剂治疗前筛查后未接受化学预防的类风湿关节炎患者结核风险显著高于接受预防者。
主要发现
- 倾向评分加权队列中预防组2249例、非预防组7225例,平均年龄57.0岁,女性81.3%。
- 生物制剂治疗2.42年期间共118例发生结核,预防组发生率0.33/100人年,非预防组0.63/100人年。
- 倾向评分加权后预防组结核风险比为0.52(95%CI 0.32-0.86)。
- 非预防组结核发生率第一年最高,随后随时间下降;预防组则持续较低。
关键数值与推荐
- 结核定义采用国际疾病分类第十版编码加抗结核药物。
- 采用倾向评分精细分层和加权控制基线混杂,Cox比例风险模型估计风险比。
临床怎么用
- 在中等结核负担地区,对筛查阴性患者启动生物制剂治疗时也应警惕结核风险,现行筛查预防策略可能不足以完全控制风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We aimed to compare tuberculosis (TB) risk during biologics treatment between patients with RA who did (prophylaxis) and did not (non-prophylaxis) undergo chemoprophylaxis following pre-biologic latent TB screening in Korea of an intermediate TB burden. METHODS: Using the 2002-16 Korea National Health Insurance database, we conducted a cohort study examining TB risk, defined by International Classification of Diseases Tenth Revision codes plus anti-TB drugs, among RA patients initiating a biologic drug with and without chemoprophylaxis after screening triage for latent TB. To control baseline confounding, we used propensity score-based fine stratification (PSS) and weighting. Cox proportional hazards models estimated hazard ratios and 95% CIs comparing TB risk between the prophylaxis vs non-prophylaxis groups. RESULTS: The PSS-weighted study cohort (mean age 57.0 years; 81.3% female) included 2249 and 7225 RA patients in the prophylaxis and non-prophylaxis groups, respectively. During 2.42 years of biologics treatment, 118 patients developed TB with the incidence rate per 100 person-years of 0.33 in the prophylaxis and 0.63 in the non-prophylaxis groups. The PSS-weighted hazard ratio (95% CI) for TB associated with the prophylaxis was 0.52 (0.32, 0.86). During the follow-up time, the incidence rate of TB remained consistently low in the prophylaxis group but it was highest in the first year, then time-dependently declined in the non-prophylaxis group. CONCLUSION: This population-based cohort study warns that the current screening-based preventive strategy generates a substantially higher TB risk after biologics initiation among screening-negative patients compared with screening-positive patients receiving chemoprophylaxis, when the background TB burden is not low.
引用
- Shin A, Lee YJ, Lee EB, et al. Tuberculosis risk with biologics by screening-guided preventive strategy in rheumatoid arthritis under intermediate tuberculosis burden. Rheumatology (Oxford). 2021. PMID: 33188421. doi:10.1093/rheumatology/keaa702
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。